Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11371036 | 0.83 | PDE10A (0.44) | CYP1A2ALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL18100998 | 0.80 | MEN1 (0.35) | CYP1A2MAPTPDE10APIK3CDPIK3CA | |
| SCHEMBL3155176 | 0.78 | CYP1A2 (0.48) | CYP1A2CYP2A6MAPTPDE10APIK3CD | |
| SCHEMBL11365421 | 0.77 | ALDH1A1 (0.44) | CYP1A2ALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL11390694 | 0.76 | ABCB11 (0.45) | CYP1A2ALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL18103465 | 0.75 | S1PR4 (0.39) | ALDH1A1MAPTPIK3CDPIK3CAPIK3CB | |
| SCHEMBL8404533 | 0.73 | CYP1A2 (0.57) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL18103464 | 0.73 | NOTUM (0.38) | ALDH1A1HPGDMAPTPIK3CDPIK3CA | |
| SCHEMBL18103468 | 0.73 | MAPT (0.35) | ALDH1A1MAPTPIK3CDPIK3CAPIK3CB | |
| SCHEMBL14359369 | 0.71 | CYP1A2 (0.44) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546156-B2 | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160280681-A1 | N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280681-A1 | N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | TK1, TNNI3K, CHUK | CYP1A2 2553/4885CYP2A6 3385/4885ALDH1A1 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.